Resumo

Objectives: SCs therapies are a new and promising approach to treating hair loss. Current treatments of AGA often fail to meet the expectations of patients and medical professionals, so there is a great need for new therapies, doubly so in the case of people with contraindications to standard methods. Our study demonstrated the curative effect of ACM therapy conducted utilizing the Regenera® procedure. Introduction: Androgenetic alopecia (AGA) is the most common form of alopecia, but treatment options are limited. This study evaluated clinical improvement in hair condition in women with AGA six months after a single injection of autologous cell micrografts (ACMs) containing hair follicle stem cells and dermal papilla cells. Materials / method: Twenty-three women with clinically and dermoscopy-confirmed AGA were included. Three 2.5 mm punch biopsies were taken from the skin of each patient with the regenera activa device. The cell suspension was prepared with the rigeneracons device and then injected into the hormone-dependent hairy zone of the scalp. Results: A significant improvement was observed on the visual analog scale (VAS) when comparing pre- and post-procedure photos (p < 0.001). The change in VAS scores was moderately negatively correlated with baseline ferritin concentration and positively with iron concentration. Improved outcomes were associated with higher baseline levels of sex hormone-binding globulin and 17α -hydroxyprogesterone. Neither testosterone nor DHT showed a significant correlation with VAS scores. Conclusion: The ACM procedure was shown to be both safe and effective, yielding satisfying results six months after a single treatment session. Future investigations should aim to gather evidence that enables the development of a cost-effective approach while minimizing treatment burden and costs.